Cardiotoxicity of the HER2 dimerisation inhibitor pertuzumab in patients with breast cancer HER2+: A systematic review

被引：0
|
作者：
Olivares Hernandez, A. [1 ]
Escala Cornejo, R. A. [2 ]
Toribio Garcia, I. [3 ]
Figuero Perez, L. [4 ]
Vidal Tocino, R. [5 ]
Miramontes Gonzalez, J. P. [6 ]
Martin Garcia, G. [4 ]
Seijas Tamayo, R. [4 ]
Cruz-Hernandez, J. J. [7 ]
Rodriguez Sanchez, C. A. [8 ]
机构：
[1] IBSAL Inst Invest Biomed Salamanca, Dept Med Oncol, Salamanca, Spain
[2] Complejo Asistencial Avila Hosp Nuestra Senora So, Dept Med Oncol, Avila, Spain
[3] Univ Hosp Leon, Cardiol, Leon, Spain
[4] Univ Hosp Salamanca, Med Oncol, Salamanca, Spain
[5] IBSAL Inst Invest Biomed Salamanca, Dept Med Oncol, Salamanca, Spain
[6] Univ Hosp Rio Hortega, Internal Med, Valladolid, Spain
[7] Hosp Clin Univ Salamanca, Med Oncol, Salamanca, Spain
[8] IBSAL Inst Invest Biomed Salamanca, Med Oncol, Salamanca, Spain
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.720
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1832P
引用
收藏
页码：S1240 / S1240
页数：1
相关论文
共 50 条
  • [1] Pertuzumab in the Treatment of HER2+ Breast Cancer
    Jhaveri, Komal
    Esteva, Francisco J.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (04): : 591 - 598
  • [2] Trastuzumab in metastatic HER2+ breast cancer: cardiotoxicity
    [J]. Reactions Weekly, 2020, 1794 (1) : 12 - 12
  • [3] Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients
    Stephanie Gu
    Stephen Dusza
    Elizabeth Quigley
    Helen Haliasos
    Alina Markova
    Michael Marchetti
    Andrea P. Moy
    Chau Dang
    Shanu Modi
    Diana Lake
    Sarah Noor
    Mario E. Lacouture
    [J]. Breast Cancer Research and Treatment, 2024, 203 : 271 - 280
  • [4] Systematic Review of HER2 Breast Cancer Testing
    Cuadros, Marta
    Villegas, Roman
    [J]. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2009, 17 (01) : 1 - 7
  • [5] HER2+ breast cancer treatment and cardiotoxicity: monitoring and management
    Guy Jerusalem
    Patrizio Lancellotti
    Sung-Bae Kim
    [J]. Breast Cancer Research and Treatment, 2019, 177 : 237 - 250
  • [6] Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer
    Fiúza M.
    [J]. Advances in Therapy, 2009, 26 (Suppl 1) : S9 - S17
  • [7] Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis
    Alhussein, Muhammad Mustafa
    Mokbel, Abir
    Cosman, Tammy
    Aghel, Nazanin
    Yang, Eric H.
    Mukherjee, Som D.
    Dent, Susan
    Ellis, Peter M.
    Dhesy-Thind, Sukhbinder
    Leong, Darryl P.
    [J]. CJC OPEN, 2021, 3 (11) : 1372 - 1382
  • [8] Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer
    Triantafyllidi, Eleni
    Triantafillidis, John K.
    [J]. BIOMEDICINES, 2022, 10 (08)
  • [9] HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer
    Harbeck, Nadia
    Beckmann, Matthias W.
    Rody, Achim
    Schneeweiss, Andreas
    Mueller, Volkmar
    Fehm, Tanja
    Marschner, Norbert
    Gluz, Oleg
    Schrader, Iris
    Heinrich, Georg
    Untch, Michael
    Jackisch, Christian
    [J]. BREAST CARE, 2013, 8 (01) : 49 - 55
  • [10] Cardiotoxicity in HER2 positive breast cancer patients treated with trastuzumab
    Lopez, M.
    Minguito Carazo, C.
    Delgado Sillero, I.
    Rojas Piedra, M.
    Tavara Silva, B.
    Lopez-Gonzalez, A.
    Castanon Lopez, C.
    Nieto Mangudo, B.
    Pedraza Lorenzo, M.
    Rodriguez Sanchez, A.
    Diz Tain, P.
    De Sande Gonzalez, L. M.
    Medina Valdivieso, S.
    Lopez Gonzalez, L.
    Honrado Franco, E.
    Garcia-Palomo, A.
    Sanchez-Cousido, L. F.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S332 - S332
12345